Kalager & Partners
19 November 2026

US Mid-Cap Quality 50: Risk Analysis

The lowest volatility of the four Systematic 50s portfolios, paired with the highest factor R² and clear evidence of mid-cap crowding.

4.1%
Ann. Return (2006–2026)
25.3%
Ann. Volatility
0.22
Sharpe Ratio (vs 0.55 Mkt)
0.90 / -5.3%
FF5 R² / Ann. Alpha

Summary

The mid-cap quality screen selects 50 U.S. non-financial stocks with a market capitalisation of at least $500 million, ranked by return on equity (ROE) from point-in-time SEC filings. Like its peers, it rebalances semi-annually in March and September to equal 2% weights.

From March 2006 to September 2026, the portfolio recorded the lowest annualised volatility of the four Systematic 50s strategies (25.3%), but returned 4.1% a year (Sharpe 0.22 vs. 0.55 for the Fama–French Market benchmark).

The Fama–French five-factor model explained 90% of daily return variation (R² = 0.90), leaving -5.3% annualised alpha (p = 0.003). Publishing this result alongside US Small-Cap Quality 50 illustrates a key empirical lesson: simple single-ratio ROE screens face far stronger valuation crowding in liquid mid-caps than in under-covered small-caps.


1. Performance Through Stress: 2006–2015 (GFC & Recovery)

In the first decade, mid-cap quality exhibited the tightest link to broad market and size factors (R² = 0.94) and took over two years to recover its 2007 peak.

  • Drawdown: From July 2007 to March 2009, the portfolio fell 60.5% from peak to trough, versus 54.6% for the market benchmark.
  • Recovery: NAV regained its pre-crisis high in 24.7 months from the trough — faster than the market’s 35.7 months, but more than twice as long as small-cap quality (11.8 months).
  • Factors: Market (+1.09), size (+0.70), profitability (+0.13) and investment (-0.18) were all statistically significant (R² = 0.94).
  • Returns: The portfolio returned 4.1% a year with 25.6% annualised volatility (Sharpe 0.24 vs. 0.38 market), losing money in 8 of 20 half-year periods.

2. Modern Market Regime: 2016–2026 (COVID-19 & Rate Cycles)

Between 2016 and 2026, equal-weighted high-ROE mid-caps suffered a deep pre-pandemic and COVID-19 drawdown while missing mega-cap technology leadership.

  • Drawdown: From September 2018 to March 2020, the portfolio fell 57.4% from peak to trough, versus 34.2% for the market benchmark.
  • Recovery: NAV recovered its prior high in 9.7 months, compared with 4.4 months for the benchmark.
  • Factors: Market (+1.03), size (+0.93) and value (+0.13) dominated the regression (R² = 0.87), while five-factor alpha was -7.3% (p = 0.008).
  • Returns: The portfolio returned 4.3% a year with 25.0% annualised volatility (Sharpe 0.20 vs. 0.74 market), posting losses in 8 of 22 half-year periods.

Full-Sample & Regime Summary

Metric Full Sample (2006–2026) 2006–2015 Regime 2016–2026 Regime
Annualised Return 4.1% (11.2% Mkt) 4.1% (7.2% Mkt) 4.3% (15.2% Mkt)
Annualised Volatility 25.3% (19.6% Mkt) 25.6% (21.0% Mkt) 25.0% (18.3% Mkt)
Sharpe Ratio 0.22 (0.55 Mkt) 0.24 (0.38 Mkt) 0.20 (0.74 Mkt)
Max Drawdown -60.5% (-54.6% Mkt) -60.5% (-54.6% Mkt) -57.4% (-34.2% Mkt)
Post-Trough Recovery 24.7 months (35.7m Mkt) 24.7 months 9.7 months (4.4m Mkt)
Negative Half-Year Periods 16 / 42 8 / 20 8 / 22
Fama–French 5-Factor R² 0.90 0.94 0.87
FF5 Annualised Alpha -5.3% (p = 0.003) -3.3% (p = 0.093) -7.3% (p = 0.008)

Conclusion

Mid-Cap Quality 50 confirms that raw ROE ranking without valuation controls or small-cap capacity constraints is not a standalone source of excess return in liquid U.S. mid-caps. Across the full 2×2 matrix on the Research Hub, both value and quality premia were materially stronger in the $50M+ small-cap universe than in the $500M+ mid-cap universe.